Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02180126

Enrollment

160

Registered

2014-07-02

Start date

2014-08-31

Completion date

2015-01-31

Last updated

2014-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Brief summary

A positive Anti-Neutrophil Cytoplasm Antibody (ANCA) test administered to patients with a high probability for vasculitis has high sensitivity and specificity for vasculitis. A positive ANCA test result in those patients who do not have a high probability for vasculitis requires extensive follow-up because those patients eventually present with malignancy or other inflammatory diseases. The investigators wish to investigate the correlation between the differing levels of positive ANCA tests and their relationship to vasculitis, malignancy and inflammatory diseases.

Interventions

OTHERFollow-up

Follow-up of of patients with borderline positive ANCA test results

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with borderline positive ANCA test results

Exclusion criteria

* Pregnant

Design outcomes

Primary

Measure	Time frame	Description
Borderline Positive ANCA	Two weeks	Borderline positive ANCA results of 12-19 U/ml is indication of possible malignancy or inflammatory diseases

Countries

Israel

Contacts

Primary ContactTatiana Sivan, MD

dk5@smile.net.il972-4-630-4648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026